Research Article
The Point on N-acetylcysteine in Idiopathic Pulmonary Fibrosis Treatment
Rindone E1 and Rosset L2*1Department of Clinical Biological Sciences, Faculty of Medicine and Surgery, San Luigi Gonzaga, University of Turin, Turin, Italy
2Faculty of Medicine and Surgery, San Luigi Gonzaga, University of Turin, Turin, Italy
- *Corresponding Author:
- Rosset L
Faculty of Medicine and Surgery
San Luigi Gonzaga, University of Turin
Turin, Italy
Tel: 393386100741
E-mail: lorenzo_rosset@yahoo.it
Received date: April 21, 2014; Accepted date: October 16, 2014; Published date: October 26, 2014
Citation: Rindone E, Rosset L (2014) The Point on N-acetylcysteine in Idiopathic Pulmonary Fibrosis Treatment. J Palliat Care Med 4:193. doi:10.4172/2165-7386.1000193
Copyright: © 2014 Rindone E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Idiopathic pulmonary fibrosis (IPF) is still a non-curable disease. The suggested therapy consists of Pirfenidone combined with other drugs like azathioprine, and acetylcysteine. The New England Journal of Medicine published a new study that goes against the common use of N-acetylcysteine (NAC) to treat IPF patient. There are other studies that went in favor of N-acetylcysteine. The present study reviews the entire developments and sums up the reality by affirming that new studies should be done to demonstrate whether the NAC should be administered in combination with Pirfenidone or not, as the last study did not clarify this point.
